News & Updates
Filter by Specialty:
Minimal monitoring feasible in HCV patients on SOF/VEL
Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.
Minimal monitoring feasible in HCV patients on SOF/VEL
26 Jul 2023
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
25 Jul 2023
Ηeparan sulphate elevated in acute exacerbations of COPD
Circulating levels of heparan sulphate (HS) are higher in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), a study has found. This increase appears to be associated with the aetiology of AECOPD.
Ηeparan sulphate elevated in acute exacerbations of COPD
25 Jul 2023
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.
